Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David S Perlin

Showing results (61-70 of 284) with videos related to

Pageof 29
Sort By:
Diagnostic Microbiology and Infectious Disease|March 16, 2005
Studies of the paradoxical effect of caspofungin at high drug concentrationsDavid A Stevens, Theodore C White, David S Perlin, et al.
Antimicrobial Agents and Chemotherapy|February 19, 2002
Molecular evaluation of the plasma membrane proton pump from Aspergillus fumigatusHenriette P Burghoorn, Patricia Soteropoulos, Padmaja Paderu, et al.
Antimicrobial Agents and Chemotherapy|August 29, 2007
A Ser678Pro substitution in Fks1p confers resistance to echinocandin drugs in Aspergillus fumigatusEleusa Maria F Rocha, Guillermo Garcia-Effron, Steven Park, et al.
Antimicrobial Agents and Chemotherapy|March 2, 2011
Evaluation of CLSI M44-A2 disk diffusion and associated breakpoint testing of caspofungin and micafungin using a well-characterized panel of wild-type and fks hot spot mutant Candida isolatesMaiken Cavling Arendrup, Steven Park, Steven Brown, et al.
Antimicrobial Agents and Chemotherapy|April 2, 2008
Reduced Candida glabrata susceptibility secondary to an FKS1 mutation developed during candidemia treatmentJohn D Cleary, Guillermo Garcia-Effron, Stanley W Chapman, et al.
Medical Mycology|March 1, 2019
Beyond tissue concentrations: antifungal penetration at the site of infectionYanan Zhao, Brendan Prideaux, Shane Baistrocchi, et al.
Antimicrobial Agents and Chemotherapy|September 17, 2008
Caspofungin-resistant Candida tropicalis strains causing breakthrough fungemia in patients at high risk for hematologic malignanciesGuillermo Garcia-Effron, Dimitrios P Kontoyiannis, Russell E Lewis, et al.
Antimicrobial Agents and Chemotherapy|January 26, 2021
Comparative Pharmacodynamics of Echinocandins against Aspergillus fumigatus Using an <i>In Vitro</i> Pharmacokinetic/Pharmacodynamic Model That Correlates with Clinical Response to Caspofungin Therapy: Is There a Place for Dose Optimization?Maria Siopi, David S Perlin, Maiken C Arendrup, et al.
Journal of Clinical Microbiology|February 5, 2010
Detection of Aspergillus fumigatus in a rat model of invasive pulmonary aspergillosis by real-time nucleic acid sequence-based amplificationYanan Zhao, Steven Park, Peter Warn, et al.
Antimicrobial Agents and Chemotherapy|June 24, 2009
Effect of Candida glabrata FKS1 and FKS2 mutations on echinocandin sensitivity and kinetics of 1,3-beta-D-glucan synthase: implication for the existing susceptibility breakpointGuillermo Garcia-Effron, Samuel Lee, Steven Park, et al.
Pageof 29

Showing results (61-70 of 284) with videos related to

Sort By:
Pageof 29
Diagnostic Microbiology and Infectious Disease|March 16, 2005
Studies of the paradoxical effect of caspofungin at high drug concentrationsDavid A Stevens, Theodore C White, David S Perlin, et al.
Antimicrobial Agents and Chemotherapy|February 19, 2002
Molecular evaluation of the plasma membrane proton pump from Aspergillus fumigatusHenriette P Burghoorn, Patricia Soteropoulos, Padmaja Paderu, et al.
Antimicrobial Agents and Chemotherapy|August 29, 2007
A Ser678Pro substitution in Fks1p confers resistance to echinocandin drugs in Aspergillus fumigatusEleusa Maria F Rocha, Guillermo Garcia-Effron, Steven Park, et al.
Antimicrobial Agents and Chemotherapy|March 2, 2011
Evaluation of CLSI M44-A2 disk diffusion and associated breakpoint testing of caspofungin and micafungin using a well-characterized panel of wild-type and fks hot spot mutant Candida isolatesMaiken Cavling Arendrup, Steven Park, Steven Brown, et al.
Antimicrobial Agents and Chemotherapy|April 2, 2008
Reduced Candida glabrata susceptibility secondary to an FKS1 mutation developed during candidemia treatmentJohn D Cleary, Guillermo Garcia-Effron, Stanley W Chapman, et al.
Medical Mycology|March 1, 2019
Beyond tissue concentrations: antifungal penetration at the site of infectionYanan Zhao, Brendan Prideaux, Shane Baistrocchi, et al.
Antimicrobial Agents and Chemotherapy|September 17, 2008
Caspofungin-resistant Candida tropicalis strains causing breakthrough fungemia in patients at high risk for hematologic malignanciesGuillermo Garcia-Effron, Dimitrios P Kontoyiannis, Russell E Lewis, et al.
Antimicrobial Agents and Chemotherapy|January 26, 2021
Comparative Pharmacodynamics of Echinocandins against Aspergillus fumigatus Using an <i>In Vitro</i> Pharmacokinetic/Pharmacodynamic Model That Correlates with Clinical Response to Caspofungin Therapy: Is There a Place for Dose Optimization?Maria Siopi, David S Perlin, Maiken C Arendrup, et al.
Journal of Clinical Microbiology|February 5, 2010
Detection of Aspergillus fumigatus in a rat model of invasive pulmonary aspergillosis by real-time nucleic acid sequence-based amplificationYanan Zhao, Steven Park, Peter Warn, et al.
Antimicrobial Agents and Chemotherapy|June 24, 2009
Effect of Candida glabrata FKS1 and FKS2 mutations on echinocandin sensitivity and kinetics of 1,3-beta-D-glucan synthase: implication for the existing susceptibility breakpointGuillermo Garcia-Effron, Samuel Lee, Steven Park, et al.
Pageof 29